ClinicalTrials.gg
Sign In
RecruitingNCT02402244Updated Aug 25, 2026

Project: Every Child for Younger Patients With Cancer

An observational study in Adrenal Gland Pheochromocytoma, Carcinoma In Situ and Central Nervous System Neoplasm, sponsored by Children's Oncology Group. Recruiting at 279 sites in 6 countries. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Children's Oncology Group · Observational

From the registry’s dates

  • Started Nov 2015; still recruiting 11 years later.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
75,000
Ages
Up to 25 Years
Sex
All
01

Study summary

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Read the detailed description

PRIMARY OBJECTIVES:

I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.

II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.

III. To develop a well annotated childhood cancer biorepository for current and future research through the collection of biospecimens (at diagnosis, time of progression, time of recurrence and/or post-mortem), including tumor, host and when feasible parental germline deoxyribonucleic acid (DNA); and key clinical data, including presentation, diagnostic, staging, summary treatment, and outcome information, from every child diagnosed with cancer at COG institutions.

IV. To allow permission to be contacted in the future to consider participating in non-therapeutic and prevention research studies involving the patient or their parents (if applicable).

V. For patients enrolled through adult cooperative groups, to develop a well annotated adolescent and young adult (AYA) cancer biorepository and to screen for eligibility for current and future research through the collection of biospecimens (at diagnosis, time of progression and time of recurrence), including tumor and host DNA; and key clinical data, including presentation, diagnostic, staging, and summary treatment information.

OUTLINE: This is an observational study. Patients are assigned to 1 of 2 protocols.

PROJECT: EVERY CHILD PROTOCOL: Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).

PROJECT AYA PROTOCOL: Patients undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).

02

Conditions studied

  • Adrenal Gland Pheochromocytoma
  • Carcinoma In Situ
  • Central Nervous System Neoplasm
  • Childhood Immature Teratoma
  • Childhood Kidney Neoplasm
  • Childhood Langerhans Cell Histiocytosis
  • Childhood Mature Teratoma
  • Congenital Mesoblastic Nephroma
  • Desmoid Fibromatosis
  • Ganglioneuroma
  • Lymphoproliferative Disorder
  • Malignant Neoplasm
  • Malignant Solid Neoplasm
  • Melanocytic Neoplasm
  • Myeloproliferative Neoplasm
  • Neoplasm of Uncertain Malignant Potential
  • Neuroendocrine Neoplasm
  • Stromal Neoplasm
03

In context

Pheochromocytoma

158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.

This study's planned enrollment of 75,000 is above the median of 184 across 56 observational studies indexed under Pheochromocytoma.

Browse Pheochromocytoma studies →

Lead sponsor

Children's Oncology Group is the lead sponsor of 448 studies on the registry; 36 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.

Browse Children's Oncology Group studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with cancer enrolled on COG therapeutic study

Eligibility criteria

Inclusion Criteria:

  • Enrollment must occur within 6 months of initial disease presentation OR within 6 months of disease, disease progression, disease recurrence, second or secondary , or post-mortem
  • Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority

  • Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:

    • All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)
    • All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
    • All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant

    • The following other benign/borderline conditions:

      • Mesoblastic nephroma
      • Teratomas (mature and immature types)
      • Myeloproliferative diseases including transient myeloproliferative disease
      • Langerhans cell histiocytosis
      • Lymphoproliferative diseases
      • Desmoid tumors
      • Gonadal stromal cell tumors
      • Neuroendocrine tumors including pheochromocytoma
      • Melanocytic tumors, except clearly benign nevi
      • Ganglioneuromas
  • Subjects must be =\< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit

  • All patients or their parents or legally authorized representatives must sign a written and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission

    • If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
75,000 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational Project AYA Protocol

    Patients undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).

    Other: Cytology Specimen Collection Procedure

  • Observational Project: Every Child Protocol

    Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal swab, saliva, cerebrospinal fluid, or urine).

    Other: Cytology Specimen Collection Procedure · Other: Medical Chart Review

Interventions

  • OtherCytology Specimen Collection Procedure

    Undergo cytology specimen collection

    Also known as: Cytologic Sampling

  • OtherMedical Chart Review

    Undergo medical data review

    Also known as: Chart Review

06

What researchers measure

Primary outcomes

  1. Number of patients who consented to biobanking

    The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.

    Time frame: Baseline

07

Study locations

253 of 279 sites recruiting

Showing the first 100 of 279 sites across 6 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2015 (actual). Primary completion is estimated for Dec 2030, 181 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2015
First posted
Mar 30, 2015
StartActual
Nov 3, 2015
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02402244
Lead sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Mar 30, 2015
Start date
Nov 3, 2015
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 25, 2026

Study contacts

Douglas S Hawkins
principal investigator · Children's Oncology Group

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pheochromocytoma →

Other studies from this sponsor

Children's Oncology Group →

Start the discussion